All tenders
75N93023F00004
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS
National Institutes of Health · United States
This contract has been awarded. Browse open opportunities
Time Left to Bid
Awarded
AwardedEducation & TrainingFederal
Basic information
- Reference number
- 75N93023F00004
- Issuing organization
- National Institutes of Health · Find award history →
- Government level
- Federal
- Solicitation type
- Education & Training
- Title
- A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS
- Source
- USASpending (Federal)
- Source ID
- usa-75N93023F00004
Details
- Location
- United States
Description
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS Awarded to: THE JOHNS HOPKINS UNIVERSITY Agency: Department of Health and Human Services Sub-agency: National Institutes of Health Award type: DELIVERY ORDER
Dates
- Publication
- 2023/08/23 12:00:00 AM UTC
- Closing date
- 2026/07/22 12:00:00 AM UTC
Estimated value
$4.6M USD
Classification
Normalized category
Education & Training